August 08, 2022, Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms……
July 28, 2022--Incyte today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura? (ruxolitinib) cream 2.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 22……
July 20, 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio? ……
June 23, 2022 —Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar? (dabrafenib) + Mekinist? (trametinib) for the treatment of adult and pediatric patients 6 years……
June 2, 2022 --Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi? (risdiplam) to include babies under two months old wi……
May 25, 2022-Sanofi and its partner Regeneron jointly announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent? (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE)……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
